Miranda LAL, Zapata TMM, Dorantes AEM, Reyes LA, Marín HD, Muñoz HO, Garduño EJ

Language: Spanish
References: 13
Page: 419-424
PDF size: 287.89 Kb.

ABSTRACT

Background. Acute lymphoblastic leukemia (ALL) is a potentially curable disease where success of the treatment depends on the timely detection of the disease; therefore, it is important to identify those influencing factors during the prediagnostic period. The objective of this study was to describe the interval time from onset of symptoms attributable to the disease to the diagnostic confirmation in terms of elapsed time (lag-time), iatrotropic stimulus and received medical care, as well as to estimate the association of these factors with mortality.
Methods. We reviewed 182 clinical files from pediatric patients with ALL in nine cancer treatment centers in Mexico and conducted interviews with their families to rebuild the run-up time until diagnosis.
Results. We included 99 living patients and 83 patients who died; average age of the patients was 7.3 ± 4.7 years. The average time between symptom onset and diagnosis was 43.5 ± 22.5 days. Patients had an average of 2.3 consultations prior to diagnostic confirmation. The main reasons for requesting medical attention were asthenia and adynamia (47.4%), fever (44.8%), pallor (44.3%), hyperoxia/anorexia (20.9%) and headache (19.9%). The number of non-oncological physicians surveyed and number of consultations until diagnosis were protective factors for mortality (OR 0.77 and 0.64, respectively).
Conclusions. Time between symptom onset and diagnostic confirmation is longer than what has been reported in developed countries mainly due to medical attention received. The number of physicians and number of prior consultations were protective factors for mortality, probably as a result of early detection and medical surveillance of nonspecific symptoms that lead to the presence of the disease.

REFERENCES

1. Ries LA, Kosary CL, Hankey BF, Miller BA, Clegg LX, Edwards BK. SEER Cancer Statistics Review, 1973-1996. Bethesda, MD: National Cancer Institute; 1999. Disponible en: http://seer. cancer.gov/csr/1973_1996/overview.pdf.

2. Dang-Tan T, Franco EL. Diagnosis delays in childhood cancer: a review. Cancer 2007;110:703-713.

3. Brown BJ, Ajayi SO, Ogun OA, Oladokun RE. Factors influencing time to diagnosis of childhood cancer in Ibadan, Nigeria. Afr Health Sci 2009;9:247-253.

4. Feinstein AR. Clinical Judgment. Baltimore: Williams and Wilkins; 1967. (reprinted: Huntington: Robert E. Krieger; 1974.)

5. Feinstein AR. Clinical Epidemiology: The Architecture of Clinical Research. Philadelphia: W. B. Saunders; 1985.

6. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978;299:926-930.

7. Knottnerus JA. Between iatrotropic stimulus and interiatric referral: the domain of primary care research. J Clin Epidemiol 2002;55:1201-1206.

8. Saha V, Love S, Eden T, Micallef-Eynaud P, MacKinlay G. Determinants of symptom interval in childhood cancer. Arch Dis Child 1993;68:771-774.

9. van Weel C. Primary care: political favourite or scientific discipline? Lancet 1996;348:1431-1432.

10. Fajardo-Gutiérrez A, Mejía-Aranguré M, Gómez-Delgado A, Mendoza-Sánchez H, Garduño-Espinosa J, Martínez-García MC. Epidemiología de las neoplasias malignas en niños residentes del Distrito Federal (1982-1991). Bol Med Hosp Infant Mex 1995;52:507-516.

11. Thulesius H, Pola J, Håkansson A. Diagnostic delay in pediatric malignancies—a population-based study. Acta Oncol 2000;39:873-876.

12. Haimi M, Peretz Nahum M, Ben Arush MW. Delay in diagnosis of children with cancer: a retrospective study of 315 children. Pediatr Hematol Oncol 2004;21:37-48.

13. Klein-Geltink J, Pogany L, Mery LS, Barr RD, Greenberg ML. Impact of age and diagnosis on waiting times between important healthcare events among children 0 to 9 years cared for in pediatric units: the Canadian Childhood Cancer Surveillance and Control Program. J Pediatr Hematol Oncol 2006;28:433-439.